辉瑞癌症研究
Cancer Therapeutics CRC (CTx)与全球制药公司辉瑞(Pfizer)达成了一项数百万美元的交易，该交易的基础是十大靠谱网投平台制药科学研究所(MIPS)进行的研究。. CTx宣布了一项为期两年的研究合作和许可协议，其中包括可能是有前景的新药开发关键的先进分子. Paul Stupple博士领导CTx的药物化学工作，并在帕克维尔的MIPS工作.
Converting the small molecules that have been identified could be a game-changer in the way cancer is treated in the future; however this is a long-term project that could take up to 10 years before patients receive the benefit of this new approach.